REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot127910.21518/1561-5936-2018-7-8-42-43Original ArticleQuadrivalent influenza vaccines: an opportunity to reduce the influenza burdenKaplya-BubenetsVeranoemail@neicon.ruRemedium071220187-8424318032022Copyright © 2018,2018Annual epidemics of influenza poses a serious risk to health of all mankind. According to WHO estimates, seasonal flu epidemics result in three to five million cases of severe illness and between 250000 and 500 000 deaths worldwide. Seasonal influenza spreads easily, with rapid transmission in crowded areas, it is difficult to protect from it, so vaccination remains the most effective method for preventing infection. For many years, the composition of influenza vaccines included two subtypes A and one type B of influenza viruses. However, since the 2012-2013 season, WHO recommends that the fourth component, the antigens of the second influenza B virus, should be included. The quadrivalent vaccines are expected to provide broader protection against infections caused by influenza B viruses.influenzavaccinationcost-effectivenessquadrivalent influenza vaccinetrivalent influenza vaccineгриппвакцинацияэкономическая эффективностьчетырехвалентная гриппозная вакцинатрехвалентная гриппозная вакцина1.Харит С.М., Рудакова А.В., Усков А.Н., Коновалова Л.Н., Лобзин Ю.В. Предотвращенный ущерб при вакцинации против гриппа 3- и 4-валентными вакцинами. Журнал инфектологии, 2017. 9(2): 17-22.2.Tisa V et al. Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden. J Prev Med Hyg, 2016 Mar, 57(1): E28-E33.3.Pieter T de Boer MSc. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States. Value in Health. 2016 December, 19(Issue 8): 964-975.4.Lisa Nagy. The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland. Pharmacoeconomics, 2016, 34: 939-951.5.Лиознов Д.А., Харит С.М. и соавт. Оценка реактогенности и иммуногенности вакцины гриппозной четырехвалентной инактивированной субъединичной. Эпидемиология и Вакцинопрофилактика, 2018, 17(3): 57-62.